|
Hereditary breast cancer -- a high cost to patient and health care provider alike
April 16, 2008Berlin, Germany: Some women who carry the BRCA gene mutation, which predisposes to breast cancer, may choose to have a prophylactic mastectomy rather than undertake lifetime surveillance, a Dutch scientist will tell the 6th European Breast Cancer Conference (EBCC-6) today (Wednesday 16 April). The mastectomy option appears to give an excellent result in avoiding breast cancer, with a remaining risk of less than 1%, Dr. Reinie Kaas, from the Surgical Department of the Netherlands Cancer Institute, Amsterdam, The Netherlands, will say.
Dr. Kaas set out to study the effects of prophylactic mastectomy in 250 patients who were BRCA carriers. "It was thought that after such a mastectomy the risk of being diagnosed with breast cancer was about 5%," she says "and therefore there was debate about whether continued surveillance was necessary or not. We decided to try to answer this question in order that women at high risk should be able to make an informed choice."
Women with mutations in the BRCA1 or BRCA2 genes have an estimated lifetime risk of developing breast cancer of about 85%. Currently strategies to deal with this risk are surveillance with monthly breast self-examination, bi-annual clinical breast examination by a physician and annual mammography plus breast MRI, or prophylactic mastectomy, where the entire breast is removed. About half of the carriers choose the latter strategy. The surveillance strategy does not prevent breast cancer, and especially in BRCA1 carriers, who mostly have fast growing tumours, 25-30% of carriers are diagnosed when the tumour is already more than 2cm in diameter.
Dr. Kaas and her team found that only one out of the 250 carriers studied was diagnosed with a breast cancer, and this was likely to be because the axillary tail (a small part of the breast that extends towards the armpit) had not been completely removed. "Our epidemiologists are investigating how many breast cancers are avoided up to the age of 80 in these women," she says. "But on current evidence we can safely state that continued follow-up, which can be costly as well as stressful for the patient, is not warranted in patients who have had a prophylactic mastectomy. Surveillance in those BRCA carriers who do not opt for mastectomy has to start at an early age, and the frequent visits to the doctor and the many examinations which need to be undertaken regularly can be a source of great stress for many women.
"However, the decision to remove healthy breasts is solely the decision of the woman, and healthcare services should not press women to make this choice simply to reduce costs."
In another presentation to the conference tomorrow (Wednesday) Dr. Yvonne Kamm, a medical oncologist from the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, will say that the costs of screening for BRCA carriers are very high, and even more so because the MRI that is used can have a high false positive rate, leading to further investigations.
"The MRI is expensive in itself, but useful because it can detect very small tumours which might not be picked up otherwise. But it also detects many other abnormalities that are not cancer, and this implies not just extra cost but also considerably anxiety for the women concerned," she says.
Between September 1999 and 2005, Dr. Kamm and her team screened 196 women at risk of hereditary breast cancer. When an abnormality was found, the women underwent further investigations. The women were screened for a median period of 2 years; this included 1149 breast examinations, 494 mammograms, and 436 MRI scans. Abnormalities led to further investigations; 32 breast examinations, 17 mammograms, 64 MRI scans, 114 ultrasound examinations, and 48 biopsies.
The cost of the first screening programme was €254 per woman year, and the extra costs of further investigations €61 per woman year. During the 6 year period 13 cancers were found.
"The total costs to find one breast cancer were high - €13168," says Dr. Kamm. We know that such intensive screening works, and that it can find breast cancer at an early stage. Therefore, we have made the choice to screen intensively women at very high risk from breast cancer."
ECCO-the European CanCer Organisation
Dr. Kaas and her team found that only one out of the 250 carriers studied was diagnosed with a breast cancer, and this was likely to be because the axillary tail (a small part of the breast that extends towards the armpit) had not been completely removed. "Our epidemiologists are investigating how many breast cancers are avoided up to the age of 80 in these women," she says. "But on current evidence we can safely state that continued follow-up, which can be costly as well as stressful for the patient, is not warranted in patients who have had a prophylactic mastectomy. Surveillance in those BRCA carriers who do not opt for mastectomy has to start at an early age, and the frequent visits to the doctor and the many examinations which need to be undertaken regularly can be a source of great stress for many women.
"However, the decision to remove healthy breasts is solely the decision of the woman, and healthcare services should not press women to make this choice simply to reduce costs."
In another presentation to the conference tomorrow (Wednesday) Dr. Yvonne Kamm, a medical oncologist from the Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, will say that the costs of screening for BRCA carriers are very high, and even more so because the MRI that is used can have a high false positive rate, leading to further investigations.
"The MRI is expensive in itself, but useful because it can detect very small tumours which might not be picked up otherwise. But it also detects many other abnormalities that are not cancer, and this implies not just extra cost but also considerably anxiety for the women concerned," she says.
Between September 1999 and 2005, Dr. Kamm and her team screened 196 women at risk of hereditary breast cancer. When an abnormality was found, the women underwent further investigations. The women were screened for a median period of 2 years; this included 1149 breast examinations, 494 mammograms, and 436 MRI scans. Abnormalities led to further investigations; 32 breast examinations, 17 mammograms, 64 MRI scans, 114 ultrasound examinations, and 48 biopsies.
The cost of the first screening programme was €254 per woman year, and the extra costs of further investigations €61 per woman year. During the 6 year period 13 cancers were found.
"The total costs to find one breast cancer were high - €13168," says Dr. Kamm. We know that such intensive screening works, and that it can find breast cancer at an early stage. Therefore, we have made the choice to screen intensively women at very high risk from breast cancer."
ECCO-the European CanCer Organisation
Breast Cancer News and Current Breast Cancer Events RSSNo need for gene screens in breast cancer families
Research reported today should provide relief to women who are worried after a relative's breast cancer diagnosis. The study in the open access journal BMC Cancer shows that a family history of breast cancer does not give a useful indication of the likelihood that a woman will develop it herself at an early age.
Over-the-counter anesthetic gel puts the squeeze on mammogram pain
The simple application of a pain-relieving gel may reduce the breast discomfort some women experience during mammography exams, according to the results of a clinical trial published in the online edition of Radiology.
First worldwide analysis of cancer survival finds wide variation between countries
Cancer survival varies widely between countries according to a worldwide study published online today in Lancet Oncology.* More than 100 investigators contributed to the study.
New Approach Sheds Light on Ways Circadian Disruption Affects Human Health
Growing evidence indicates that exposure to irregular patterns of light and darkness can cause the human circadian system to fall out of synchrony with the 24-hour solar day, negatively affecting human health - but scientists have been unable to effectively study the relationship between circadian disruptions and human maladies.
Improving understanding of cell behaviour in breast cancer
The invasion and spread of cancer cells to other parts of the body, known as metastasis, is a principal cause of death in patients diagnosed with breast cancer.
Vitamin A pushes breast cancer to form blood vessel cells
Researchers at Georgetown University Medical Center have discovered that vitamin A, when applied to breast cancer cells, turns on genes that can push stem cells embedded in a tumor to morph into endothelial cells. These cells can then build blood vessels to link up to the body's blood supply, promoting further tumor growth.
Study finds that significant proportion of men told wife's cancer was incurable late or not at all
A study conducted in Sweden found that more than 40 percent of widowers in that country whose wives died from cancer four or five years earlier reported they were either never told that their spouse's cancer was incurable, or they heard this information during the last week of her life.
Insect warning colors aid cancer and tropical disease drug discovery
Brightly colored beetles or butterfly larvae nibbling on a plant may signal the presence of chemical compounds active against cancer cell lines and tropical parasitic diseases, according to researchers at Smithsonian's Tropical Research Institute in Panama.
New ovarian stimulation technique offers more cancer patients the chance to preserve their fertility
Researchers have shown for the first time that it is possible to stimulate a woman's ovaries to produce eggs for collection during the final phase of the menstrual cycle.
Should embryos with a hereditary disorder be transferred if no unaffected embryos are available?
The numbers of cycles of preimplantation genetic diagnosis or screening are rising steadily in Europe with over 2,700 reported in 2004 (the most recent year for which data are available).
More Breast Cancer News Articles
 | Courageous Souls: Do We Plan Our Life Challenges Before Birth? by Robert Schwartz |
 | What Your Doctor May Not Tell You About Menopause (TM): The Breakthrough Book on Natural Hormone Balance by John R. Lee, Virginia Hopkins |
 | Lopsided: How Having Breast Cancer Can Be Really Distracting by Meredith Norton |
 | Dr. Susan Love's Breast Book:4th Edition 2005 by Susan Love |
 | The Middle Place (Voice) by Kelly Corrigan |
 | 7 Weeks to Safe Social Drinking: How to Effectively Moderate Your Alcohol Intake by Donna J. Cornett |
 | Breast Cancer Husband : How to Help Your Wife (and Yourself) during Diagnosis, Treatment and Beyond by Marc Silver |
 | Just Get Me Through This!: The Practical Guide to Breast Cancer by Deborah A. Cohen, M.D., Robert M. Gelfand |
 | Pretty Is What Changes: Impossible Choices, The Breast Cancer Gene, and How I Defied My Destiny by Jessica Queller |
 | Don't Bet against Me!: Beating the Odds Against Breast Cancer and in Life by Deanna Favre, Angela Elwell Hunt |
| © 2008 BrightSurf.com |